News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
c402.market's mechanism design is more inclined to incentivize token creators, rather than just benefiting minters and traders.
A one-person media company, ushering in the era of everyone as a Founder.
The platform serves as a foundation, enabling thousands of applications to be built and profit.
If the price falls back to the $55,000-$70,000 range, it would be a normal cyclical movement rather than a signal of systemic collapse.
In Brief DYDX launches zero fee initiative to boost on-chain trading platform usage. The move aims to increase user participation and improve DYDX's market dynamics. DYDX faces challenges with declining TVL and user interest amidst market uncertainties.
- 22:10The probability of a Fed rate cut in December is 64.1%, and the probability of a rate cut in January next year is 54.1%.ChainCatcher news, according to Golden Ten Data, CME "FedWatch" shows that the probability of the Federal Reserve cutting interest rates by 25 basis points in December is 64.1%, while the probability of keeping rates unchanged is 35.9%. By January next year, the probability of a cumulative 25 basis point rate cut is 54.1%, the probability of keeping rates unchanged is 23.2%, and the probability of a cumulative 50 basis point rate cut is 22.7%.
- 22:08Biotech company Propanc raises $100 million for crypto reserves and cancer therapy developmentJinse Finance reported that Australia-based Propanc Biopharma (NASDAQ: PPCB) announced on Monday that it has secured up to 100 million dollars in financing from Hexstone Capital. Hexstone Capital is a family office active in the fields of bitcoin, ethereum, solana, dogecoin, and other digital assets. This private placement deal, structured through convertible preferred shares, provides Propanc with an initial investment of 1 million dollars and up to an additional 99 million dollars in follow-up financing over the next year. The proceeds will be used to build Propanc's digital asset portfolio and accelerate the development of its leading tumor therapy, PRP, which is currently targeted for its first human trial in 2026. CEO James Nathanielsz described this move as a "transformational phase," though the company did not specify which digital assets it plans to acquire.
- 21:29The US Dollar Index fell by 0.02% on the 10th.Jinse Finance reported that the US Dollar Index fell by 0.02% on the 10th, closing at 99.589 in the late foreign exchange market.